NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

A journal does not prevent one from releasing TLD, but ASCO Embago Policy does. So perhaps, tonight we learn our fate OR perhaps we do not as we will have to wait until June 3rd. Or do we....

Does 38,7% approximate 36.6% which both slightly over estimate the actual because placebo is not placebo only, it is placebo plus rGBM crossover, and (DCVAX )100 is not DCVAX alone it is (DCVAX plus crossover before recurrent DCVAX). Which leads me to guesstimate that 35% vs 15% is highly statistically significant. AND at five years this gap remains fairly consistent so that 17-19% grows when the final 100 DCVAXers walk through giving about 21-22% which according to Utah Liau gives you about 25+% vs 5ish% which too is highly statistically significant.

This also tells you that early is significantly different than late when one KM curve over 12years is compared to another that may end around 7 years.

So it does not matter in the long run whether it is a journal or ASCO, but this marketer will tell you that ASCO should and requires that they come first.

What matters is that Linda Powers has already won, that she knows she has won, and that we all know what we are worth!! Which is not $10 or even $26, it is substantially higher.

SYNERGY, GESTALT, SCHADENFREUDE